Therapeutic Antibody
Development Overview
On This Page |
Solution | Why Bio-Rad | Our Expertise | Resources |
Develop Better, Faster with Bio-Rad
Bring higher levels of efficiency, accuracy, and quality to your therapeutic antibody development programs with the latest technologies, proven products, and customer-focused services from Bio-Rad.
Start a Conversation with a SpecialistThe market for therapeutic antibodies continues to grow,1,2 fueled in part by the financial returns from products already on the market, the opening for biosimilars as successful products come off-patent, and advances in technologies for discovery and development. With this growth, teams developing therapeutic antibodies are under a lot of pressure to reach first-in-human studies as quickly as possible. At the same time, those antibodies must be robust, efficacious, and safe.
New technologies and scientifically experienced service partners are a powerful resource that can help therapeutic antibody development teams maximize data quality in the minimum amount of time.
With a proven track record of innovation, quality, and customer support that spans decades, Bio-Rad has helped leading and emerging biopharma companies advance their antibody discovery and development pipelines.
We are ready to use this wealth of expertise to help you and your teams develop safe and effective therapeutic antibodies as efficiently as possible.
-
Did you know?
While the average time from lead identification to IND was 10—12 months immediately before the pandemic,3 Bamlanivimab, one of the antibodies developed to treat COVID-19, moved from discovery to first-in-human studies in 90-days.4
Improve Efficiency from Antibody Discovery to IND
Cell Line Development
Streamline cell line characterization using less sample with ddPCR
Custom Antibody Generation
Develop better PK and ADA assays faster with highly sensitive and specific custom monoclonals that are produced quickly and consistently
High-Throughput Antibody Screening
Maximize productivity with robust, automation-ready high speed flow cytometry
Monoclonal Antibody Purification
Find resins for challenging purifications using the help of our highly experienced bioprocess development scientists
Advance Therapeutic Antibody Development with a Proven Partner
For scientists that have extensive experience in therapeutic antibody discovery and development, Bio-Rad provides products, services, and support that help you generate actionable data quickly, confidently, and cost-effectively.
Rapidly generate and screen antibody candidates to find those that match the intended affinity and specificity profile
Design and execute assays to characterize the efficacy, ADME, safety, and PK/PD of candidates in a high-throughput setting
Efficiently characterize the efficacy, ADME, safety, and PK/PD of candidates using recombinant antibodies
Find a cell line that efficiently produces material and meets scale needs
Optimize your lead cell line and its media to improve productivity and cost of goods
Identify biomarkers to monitor either disease progression or treatment safety and efficacy
Efficiently purify antibodies while maximizing recovery and yield
Perform product quality control and certification of analysis
Leverage Our Scientific Expertise to Overcome Your Challenges
Webinars
How to Improve Your Antibody Drug Development Assays with Anti-Idiotypic Antibodies
Discover how recombinant monoclonal anti-idiotypic antibodies are generated at Bio-Rad, our unique capabilities for developing antibodies against drug-target complexes, and how our antibodies can be used to develop highly specific and sensitive PK and ADA assays.
Optimization to Automation:
The Advantages of Multidimensional
(Multi-D) ChromatographyLearn the advantages of automated multidimensional (Multi-D) chromatography compared to traditional multi-step purification strategies. Case studies include automating a 4-column monoclonal antibody purification.
Articles
Unveiling Key Strategies for Next-Generation Biotherapeutics
Explore significant breakthroughs that are paving the way for biotherapeutic development and revolutionizing the way we approach medicine.
The Antibody Saga – Key Milestones and Big Predictions
We take a look at the most impactful recent trends of antibody therapeutics over the last two years.
Meet the New Wave of Therapeutic Antibodies
We look into how new modalities are paving the way for better antibody-based therapies and the potential headaches they bring with them.
Ensuring Safety Throughout the Antibody Development Process
We look into the importance of demonstrating safety throughout antibody development, manufacturing, and QC. Find tools and processes that address challenges.
Antibody Discovery – What the Future Holds
We assess the trends and pain points in therapeutic antibody discovery and look to the future. Take a look at the predictions.
Meeting Regulatory Assay Guidelines When Developing Therapeutic Antibodies
Therapeutic antibody development has regulatory guidelines. We look at the best ways to meet them and provide some essential tips.
How Custom Antibody Libraries Empower Therapeutic Antibody Bioassays
We assess the value of the new custom tools available and how they are helping advance novel therapeutic antibodies.
Optimizing mAb Purification: Resin Selection Using DOE Screening
Using a systematic approach, such as DOE screening, can reduce the complexity with selecting resins for monoclonal antibody purification. Find expert tips.
Detecting Contaminants During Therapeutic Antibody Production
Learn how new technologies reduce contamination risks in monoclonal antibody therapeutics manufacturing. Find tips for optimizing impurities detection.
Considerations for Scaling-Up Purification Processes
Learn key considerations for scale-up of chromatography operations and tips from experts for streamlining the antibody production process.
Overcoming Monoclonal Antibody Purification Challenges
Learn critical success factors for monoclonal antibody purification and strategies you can leverage to accelerate production.
Resources
Publications
Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV-2 Antibody
Read how the ZE5 Cell Analyzer allowed rapid selection of SARS-CoV-2 neutralizing antibodies.
Using Flow Cytometry to Advance Therapeutic Antibody Developmentx
Learn advancements in flow cytometry that take it from a technique to a powerful tool that goes beyond instrumentation.
Documents
Why Flow Cytometry is Ideal for Lead Candidate Screening
Learn how flow cytometry played a crucial role in the discovery and development of novel therapies for SARS-CoV-2 from research papers published.
Using Flow Cytometry to Advance Therapeutic Antibody Development
Rapid, accurate lead candidate identification is easy with the right tools. We describe the benefits of using flow cytometry to perform cell-based assays.
-
Maximizing Screening Speed and Throughput with Flow Cytometry
This infographic highlights challenges for high-throughput flow cytometry and how the ZE5 Cell Analyzer has solutions to overcome them.
References
- MAb Products: Market Trends and Projections. BioProcess International. Published October 31, 2020. Accessed December 6, 2021. https://bioprocessintl.com/business/economics/the-market-for-therapeutic-mab-products/
- Dealmakers B. Moving up with the monoclonals. Biopharma Deal. Published online September 19, 2019. doi:10.1038/d43747-020-00765-2
- Kelley B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol. 2020;38(5):540-545. doi:10.1038/s41587-020-0512-5
- AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19. Published January 27, 2021. Accessed December 6, 2021. https://www.businesswire.com/news/home/20210127005492/en/AbCellera-Discovered-Antibody-Bamlanivimab-to-be-Developed-with-VIR-7831-for-the-Treatment-of-COVID-19
Receive Updates
Keep up to date with useful tips and online resources to continuously improve your therapeutic antibody development workflows. Sign up to be notified when new resources like publications, protocols, webinars, and how-to videos become available.